Last reviewed · How we verify
NCT03418181: IncrementalHD
Does Incremental Initiation of Haemodialysis Preserve Native Kidney Function?
NA trial testing Standard Haemodialysis in Kidney Failure in 50 participants. Status unknown.
2 January 2019
Quick facts
| Lead sponsor | East and North Hertfordshire NHS Trust |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 8 January 2018 |
| Primary completion | 2 January 2019 |
| Estimated completion | 2 March 2019 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Standard Haemodialysis
- Incremental dialysis
Conditions studied
- Kidney Failure — all drugs for Kidney Failure →
- Dialysis — all drugs for Dialysis →
Sponsor
East and North Hertfordshire NHS Trust
Who can join
18 and older, any sex, with Kidney Failure or Dialysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients who start haemodialysis usually retain some natural kidney function for months or years after starting dialysis. Even a small amount of this natural kidney function can be helpful in reducing the need for dietary and fluid restriction. There is also good evidence that retaining a small amount of natural kidney function may provide a survival benefit for patients on dialysis. Most patients who commence haemodialysis start three times per week for 3.5-4 hours per session, irrespective of the amount of natural kidney function they may have. An alternative approach used in some kidney units is to take account of the natural kidney function in prescribing the amount of dialysis. This may allow patients to start treatment needing to spend less time on dialysis or even to start just twice weekly. The amount of dialysis can be adjusted over time as natural kidney function declines. This is called "incremental haemodialysis". Both of these approaches are considered to be standard care although it is not known which approach is more beneficial to patients. There are some suggestions that the frequency of dialysis may influence the rate of decline of natural kidney function but this need to be tested in a large randomised study. To inform the design of such a study, a smaller scale feasibility study is required. We intend to randomise fifty new starters on haemodialysis with adequate natural kidney function into two groups - a group who will have dialysis prescribed in the standard fashion - three times weekly for 3.5-4 hours per session or a group who will have an incremental start beginning with twice weekly treatment. We will investigate how many patients have sufficient natural kidney function to be eligible, whether patients are willing to participate and continue in the study, compare the rate of loss of kidney function between groups, and ascertain whether this individualised dialysis approach is less intrusive to patients. The results will be used to design a larger definitive study.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Narrative Review of Incremental Hemodialysis.
Murea M, Moossavi S, Garneata L, Kalantar-Zadeh K. · · 2020 · cited 38× · PMID 32043027 · DOI 10.1016/j.ekir.2019.11.014 -
Impact of incremental versus conventional initiation of haemodialysis on residual kidney function: study protocol for a multicentre feasibility randomised controlled trial.
Kaja Kamal RM, Farrington K, Wellsted D, Sridharan S, et al · · 2020 · cited 11× · PMID 32792431 · DOI 10.1136/bmjopen-2019-035919 -
Incremental dialysis: two complementary views.
Casino DFG, Murea M, Floege MJ, Zoccali C. · · 2024 · cited 7× · PMID 38404364 · DOI 10.1093/ckj/sfae020 -
Incremental versus standard dialysis for people with kidney failure
Sabanayagam D, Hegerty K, Au E, Beruni N, et al · · 2023
Verify or expand the search:
- PubMed search for NCT03418181
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Failure
Currently open trials in the same condition.
- NCT07492511 — Renal and Hepatic Abnormal Doppler Patterns in Trauma · recruiting
- NCT06243731 — A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation · recruiting
- NCT06642597 — STarting incrEmental Prescription of Peritoneal Dialysis · NA · recruiting
- NCT06343727 — A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF) · NA · recruiting
- NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
Other East and North Hertfordshire NHS Trust trials
Trials by the same sponsor.
- NCT07069998 — AI-guided AF Treatment · NA · not yet recruiting
- NCT06915909 — Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial · NA · not yet recruiting
- NCT06863090 — In Vivo Dosimetry for Brachytherapy Study · recruiting
- NCT06623123 — Oto Smartphone App in Treating Tinnitus Amongst Adult Patients Compared with Standard Talking Therapies · Phase 3 · recruiting
- NCT06400927 — Safety of AI-Powered Virtual Assistant in Outpatient Management of Heart Failure · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03418181 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by East and North Hertfordshire NHS Trust
- Last refreshed: 1 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03418181.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing